BUPROPION HYDROCHLORIDE (XL)- bupropion hydrochloride tablet, extended release

Valsts: Amerikas Savienotās Valstis

Valoda: angļu

Klimata pārmaiņas: NLM (National Library of Medicine)

Aktīvā sastāvdaļa:

BUPROPION HYDROCHLORIDE (UNII: ZG7E5POY8O) (BUPROPION - UNII:01ZG3TPX31)

Pieejams no:

Exelan Pharmaceuticals Inc.

SNN (starptautisko nepatentēto nosaukumu):

BUPROPION HYDROCHLORIDE

Kompozīcija:

BUPROPION HYDROCHLORIDE 300 mg

Ievadīšanas:

ORAL

Receptes veids:

PRESCRIPTION DRUG

Ārstēšanas norādes:

Bupropion hydrochloride extended-release tablets, (XL) is indicated for the treatment of major depressive disorder (MDD), as defined by the Diagnostic and Statistical Manual (DSM). The efficacy of the immediate-release formulation of bupropion was established in two 4-week controlled inpatient trials and one 6-week controlled outpatient trial of adult patients with MDD. The efficacy of the sustained-release formulation of bupropion in the maintenance treatment of MDD was established in a long-term (up to 44 weeks), placebo-controlled trial in patients who had responded to bupropion in an 8-week study of acute treatment [see Clinical Studies (14.1)]. Bupropion hydrochloride extended-release tablets, (XL) is indicated for the prevention of seasonal major depressive episodes in patients with a diagnosis of seasonal affective disorder (SAD). The efficacy of bupropion hydrochloride extended-release tablets, (XL) in the prevention of seasonal major depressive episodes was established in 3 placebo-controlled trials

Produktu pārskats:

Bupropion hydrochloride extended-release tablets, USP (XL), 150 mg are white to off white capsule shaped, biconvex coated tablets de-bossed with ‘I’ on one side and ‘13’ on the other side and are available in bottles of 30 tablets (NDC 76282-480-30). Bupropion hydrochloride extended-release tablets, USP (XL), 150 mg are white to off white capsule shaped, biconvex coated tablets de-bossed with ‘I’ on one side and ‘13’ on the other side and are available in bottles of 90 tablets(NDC 76282-480-90). Bupropion hydrochloride extended-release tablets, USP (XL), 150 mg are white to off white capsule shaped, biconvex coated tablets de-bossed with ‘I’ on one side and ‘13’ on the other side and are available in bottles of 500 tablets (NDC 76282-480-05). Bupropion hydrochloride extended-release tablets, USP (XL), 300 mg are white to off white capsule shaped, biconvex coated tablets de-bossed with ‘I 71’ on one side and plain on the other side and are available in bottles of 30 tablets (NDC 76282-481-30). Bupropion hydrochloride extended-release tablets, USP (XL), 300 mg are white to off white capsule shaped, biconvex coated tablets de-bossed with ‘I 71’ on one side and plain on the other side and are available in bottles of 90 tablets (NDC 76282-481-90). Bupropion hydrochloride extended-release tablets, USP (XL), 300 mg are white to off white capsule shaped, biconvex coated tablets de-bossed with ‘I 71’ on one side and plain on the other side and are available in bottles of 500 tablets (NDC 76282-481-05). Store at bupropion HCl extended-release tablets at room temperature between 20° to 25°C (68°F to 77°F) [see USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP.

Autorizācija statuss:

Abbreviated New Drug Application

Lietošanas instrukcija

BUPROPION HYDROCHLORIDE (XL)- BUPROPION HYDROCHLORIDE TABLET, EXTENDED
RELEASE
Exelan Pharmaceuticals Inc.
----------
MEDICATION GUIDE
Bupropion Hydrochloride Extended-Release Tablets, USP (XL)
(bue proe' pee on hye'' droe klor' ide)
IMPORTANT: Be sure to read the three sections of this Medication
Guide. The first section is about the
risk of suicidal thoughts and actions with antidepressant medicines;
the second section is about the risk of
changes in thinking and behavior, depression and suicidal thoughts or
actions with medicines used to quit
smoking; and the third section is entitled “What Other Important
Information Should I Know About
bupropion hydrochloride extended-release tablets (XL)?”
Antidepressant Medicines, Depression and Other Serious Mental
Illnesses, and Suicidal Thoughts or
Actions
This section of the Medication Guide is only about the risk of
suicidal thoughts and actions with
antidepressant medicines.
What is the most important information I should know about
antidepressant medicines, depression and
other serious mental illnesses, and suicidal thoughts or actions?
1. Antidepressant medicines may increase the risk of suicidal thoughts
or actions in some children,
teenagers, or young adults within the first few months of treatment.
2. Depression or other serious mental illnesses are the most important
causes of suicidal thoughts and
actions. Some people may have a particularly high risk of having
suicidal thoughts or actions. These
include people who have (or have a family history of) bipolar illness
(also called manic-depressive
illness) or suicidal thoughts or actions.
3. How can I watch for and try to prevent suicidal thoughts and
actions in myself or a family member?
•
Pay close attention to any changes, especially sudden changes, in
mood, behaviors, thoughts, or
feelings. This is very important when an antidepressant medicine is
started or when the dose is
changed.
•
Call your healthcare provider right away to report new or sudden
changes in mood, behavior,
thoughts, or feelings.
�

Produkta apraksts

BUPROPION HYDROCHLORIDE (XL)- BUPROPION HYDROCHLORIDE TABLET, EXTENDED
RELEASE
EXELAN PHARMACEUTICALS INC.
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
BUPROPION HYDROCHLORIDE EXTENDED-RELEASE TABLETS (XL) SAFELY AND
EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR
BUPROPION HYDROCHLORIDE EXTENDED-RELEASE TABLETS (XL).
BUPROPION HYDROCHLORIDE EXTENDED-RELEASE TABLETS (XL), FOR ORAL USE
INITIAL U.S. APPROVAL: 1985 WARNING: SUICIDAL THOUGHTS AND BEHAVIORS
_ SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._
INCREASED RISK OF SUICIDAL THINKING AND BEHAVIOR IN CHILDREN,
ADOLESCENTS, AND YOUNG ADULTS TAKING ANTIDEPRESSANTS. MONITOR FOR
WORSENING AND EMERGENCE OF SUICIDAL THOUGHTS AND
BEHAVIORS. (5.1)
MONITOR FOR WORSENING AND EMERGENCE OF SUICIDAL THOUGHTS AND
BEHAVIORS. ( 5.1)
INDICATIONS AND USAGE
Bupropion hydrochloride is an aminoketone antidepressant, indicated
for:
treatment of major depressive disorder (MDD) (1.1)
prevention of seasonal affective disorder (SAD) (1.2)
DOSAGE AND ADMINISTRATION
General:
• Increase dose gradually to reduce seizure risk. (2.1, 5.3)
• Periodically reassess the dose and need for maintenance treatment.
(2.2)
Major Depressive Disorder
• Starting dose: 150 mg once daily. Usual target dose: 300 mg once
daily (2.2)
• After 4 days, may increase the dose to 300 mg once daily. (2.2)
Seasonal Affective Disorder
• Initiate treatment in the autumn prior to onset of seasonal
depressive symptoms. (2.3)
• Starting dose: 150 mg once daily. Usual target dose: 300 mg once
daily. (2.3)
• After one week, may increase the dose to 300 mg once daily. (2.3)
• Continue treatment through the winter season. (2.3)
Hepatic Impairment
• Moderate to severe hepatic impairment: 150 mg every other day
(2.6)
• Mild hepatic impairment: Consider reducing the dose and/or
frequency of dosing. (2.6, 8.7)
Renal Impairment
• Consider reducing the dose and/or frequency of dosing. (2.7, 8.6)
DOSAGE FORMS AND STRENGTHS
Exten